X4 Pharmaceuticals

Historical price data

X4 Pharmaceuticals is a publicly traded biotech focused on rare immune disorders, leveraging its expertise in the CXCR4 pathway. The company achieved a major milestone with the 2024 FDA approval and U.S. launch of XOLREMDI® for WHIM syndrome, its first commercial product. X4 is now advancing mavorixafor into a pivotal Phase 3 trial for chronic neutropenia and has established commercialization partnerships in Europe and the Middle East, positioning itself as a commercial-stage rare disease company.

Platform focused on targeting the CXCR4/CXCL12 pathway, a key regulator of white blood cell mobilization from bone marrow, using oral small molecule antagonists.

11 drugs in pipeline, 2 in Phase 3

In WHIM syndrome, XOLREMDI® is first-to-market with no direct competitors. In chronic neutropenia, it competes against established injectable G-CSF therapies. Key differentiation is oral, once-daily dosing and targeted mechanism of action via CXCR4 inhibition.